Versantis to Advance New Generation of Liver Disease Medicines
Funding brings resources to advance lead candidate VS-01 to first-in-human study and transform the care of patients with rare and life-threatening liver diseases.
Zurich, Switzerland, March 29th 2017 – Versantis, a pharmaceutical company focused on the development of products addressing a high unmet medical need in the diagnosis, prevention, and treatment of liver diseases, today announces the closing of a Series A financing round of CHF 4.4 million (USD 4.4 million). Redalpine Venture Partners led the round and was joined by Altus Partners, HealthEquity, Occident Group, Zürcher Kantonalbank, and private investors. The proceeds will be used to progress the lead candidate, VS-01, into a Phase I/II clinical trial targeting hepatic encephalopathy in acute on chronic-liver-failure, as well as to further develop the company’s preclinical pipeline.